Microalbuminuria prevalence study (MAPS) in hypertensive patients with type 2 diabetes in Thailand

Journal of the Medical Association of Thailand

Volumn 88, Issue 11, 2005, Pages 1624-1629

  Buranakitjaroen, Peera ^a   Deerochanawong, Chaicharn ^b   Bunnag, Pongamorn ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b RAJAVITHI HOSPITAL   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Albuminuria; Diabetic nephropathy; Hypertension; Renin angiotensin system; Thailand

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BACTERIURIA; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; THAILAND; TREATMENT OUTCOME; ALBUMINURIA; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; MIDDLE AGED; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; URINE;

ALBUMINURIA; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; RENIN-ANGIOTENSIN SYSTEM; THAILAND; TIME FACTORS;

EID: 33645220783     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dodson PM. Hypertension and diabetes. Curr Med Res Opin 2002; 18(Suppl 1): s48-57.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
3. Diabetes e-Atlas, International Diabetes Foundation website [ONLINE]. Available at: http://www.idf.org/e-atlas/home. Accessed 6 January 2004.
4. Aekplakorn W, Stolk RP, Neal B, Suriyawongpaisal P, Chongsuvivatwong V, Cheepudomwit S, et al. The prevalence and management of diabetes in Thai adults: the international collaborative study of cardiovascular disease in Asia. Diabetes Care 2003; 26: 2758-63.
5. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-8.
6. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 2039.
7. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 1996; 19: 305-12.
8. American Diabetes Association. Diabetic nephropathy. Position Statement. Diabetes Care 2002; 25(Suppl 1): 85S-9S.
9. Spooren PF, Lekkerkerker JF, Vermes I. Micral-test: a qualitative dipstick test for micro-albuminuria. Diabetes Res Clin Pract 1992; 18: 83-7.
10. Mather HM, Chaturvedi N, Kehely AM. Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus. Diabet Med 1998; 15: 672-7.
11. Tomura S, Kawada K, Saito K, Lin YL, Endou K, Hirano C, et al. Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Am J Nephrol 1999; 19: 13-20.
12. Lee WR, Lim HS, Thai AC, Chew WL, Emmanuel S, Goh LG, et al. A window on the current status of diabetes mellitus in Singapore - the Diabcare-Singapore 1998 study. Singapore Med J 2001; 42: 501-7.
13. Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005; 48: 17-26.
14. American Diabetes Association. Position statement: standards of medical care for patients with diabetes mellitus. Diabetes Care 1999; 22(Suppl 1): S32-41.
15. Parving HH, Osterby R, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The kidney. Philadelphia: Saunders, 2000: 1731-73.
16. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
17. Ball SG. Benefits of blood pressure reduction in diabetic patients. J Hypertens Suppl 2003; 21 (Suppl 6): S31-6.
18. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
20. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44(Suppl 2): 14S-21S.
21. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-9.
22. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27: 997-1002.
23. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
24. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
25. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.